Genmab acquires the Dutch biotech for $8bn.

BNT329 enters the clinic, as do four other new ADCs.

Four more failed tiragolumab trials, including Imbrave-152, will feature.

Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.

ALE.P03 is the biotech's third anti-Claudin1, and its second ADC.